Bringing automated next-generation sequencing to every oncology clinic
5 Jan 2026
Kathy Davy, President of Clinical Next Generation Sequencing at Thermo Fisher Scientific, shares how the Genexus Dx system is transforming precision oncology in the United States. By fully automating the next-generation sequencing (NGS) workflow, from nucleic acid extraction to results, Genexus Dx and the Oncomine Dx Express test empower even small and community hospitals to deliver rapid, high-quality genomic insights in-house. This breakthrough closes critical access gaps, enabling faster, more informed treatment decisions for cancer patients. With FDA approval as a companion diagnostic for targeted lung cancer therapy and broad tumor profiling capabilities, this solution brings advanced testing directly to where patients are treated. Looking ahead, the integration of AI promises to further accelerate data analysis and help clinicians match patients to the best therapies with unprecedented speed and accuracy.
This interview was recorded for CLINICAL24 2025
About the company
Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
